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Abstract
Introduction: Adolescents and youth receiving antiretroviral treatment (ART) in sub-Saharan Africa have high attrition and
inadequate ART outcomes, and evaluations of interventions improving ART outcomes amongst adolescents are very limited.
Sustainable Development Goal (SDG) target 3c is to substantially increase the health workforce in developing countries. We
measured the effectiveness and cost-effectiveness of community-based support (CBS) provided by lay health workers for ado-
lescents and youth receiving ART in South Africa.
Methods: A retrospective cohort study including adolescents and youth who initiated ART at 47 facilities. Previously unem-
ployed CBS-workers provided home-based ART-related education, psychosocial support, symptom screening for opportunistic
infections and support to access government grants. Outcomes were compared between participants who received CBS plus
standard clinic-based care versus participants who received standard care only. Cumulative incidences of all-cause mortality
and loss to follow-up (LTFU), adherence measured using medication possession ratios (MPRs), CD4 count slope, and virological
suppression were analysed using multivariable Cox, competing-risks regression, generalized estimating equations and mixed-
effects models over five years of ART. An expenditure approach was used to determine the incremental cost of CBS to usual
care from a provider perspective. Incremental cost-effectiveness ratios were calculated as annual cost per patient-loss
(through death or LTFU) averted.
Results: Amongst 6706 participants included, 2100 (31.3%) received CBS. Participants who received CBS had reduced mor-
tality, adjusted hazard ratio (aHR) = 0.52 (95% CI: 0.37 to 0.73; p < 0.0001). Cumulative LTFU was 40% lower amongst par-
ticipants receiving CBS (29.9%) compared to participants without CBS (38.9%), aHR = 0.60 (95% CI: 0.51 to 0.71);
p < 0.0001). The effectiveness of CBS in reducing attrition ranged from 42.2% after one year to 35.9% after five years. Viro-
logical suppression was similar after three years, but after five years 18.8% CBS participants versus 37.2% non-CBS partici-
pants failed to achieve viral suppression, adjusted odds ratio = 0.24 (95% CI: 0.06 to 1.03). There were no significant
differences in MPR or CD4 slope. The cost of CBS was US$49.5/patient/year. The incremental cost per patient-loss averted
was US$600 and US$776 after one and two years, respectively.
Conclusions: CBS for adolescents and youth receiving ART was associated with substantially reduced patient attrition, and is
a low-cost intervention with reasonable cost-effectiveness that can aid progress towards several health, economic and equal-
ity-related SDG targets.
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1 | INTRODUCTION
The UN Sustainable Development Goals (SDGs) are 17 uni-
versal, ambitious and interrelated goals established to guide
the development policy and agenda of member states till
2030 [1]. UNAIDS has also set ambitious HIV treatment tar-
gets to help end the AIDS epidemic by 2030 (SDG 3.3) [2].
For the SDGs to be achievable, evidence-based interventions
need to be implemented [3], and to reach the UNAIDS treat-
ment goals, innovative and efficient healthcare service delivery
models are required [4].
Amongst adolescents in sub-Saharan Africa (SSA), progress
towards the SDGs and HIV prevention and care goals are par-
ticularly lagging [5,6]. Adolescents in SSA have the highest
HIV incidence globally [7,8], and adolescents are the only
demographic group in whom AIDS-related mortality is
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increasing, having tripled since 2000 [9,10]. Adolescents and
youth receiving antiretroviral treatment (ART) have poorer
patient retention and treatment outcomes than adults [11-15].
Ensuring high retention is a crucial aspect of the ART pro-
gramme to maximize treatment outcomes [16], as well as to
reduce community viral load to prevent horizontal transmis-
sion [17,18]. ART programmes retention in SSA is poor, being
only 56% after five years [19]. The barriers to retention
amongst adolescents and youth are numerous and diverse,
and include the burden of multiple vulnerabilities, barriers to
healthcare access, mental health needs, a lack of psychosocial
support, a lack of trained healthcare workers focusing on ado-
lescent-specific care, and lack of support during the transition
from paediatric to adult care [20-23]. Appropriate, individual-
ized, holistic and durable interventions that support adoles-
cent’s clinical, psychosocial and nutritional care have been
suggested [20,21,23].
In SSA, adolescents and youth form the greatest proportion
of the population (over 33%), and SSA is the only region in
which this group continues to grow substantially [24]. The
health of adolescents is crucial that they may meaningfully
contribute to the economy [25,26]. Their economic potential
will support progress towards SDGs 1, 2, 8 and 9 to reduce
poverty and hunger, promote economic growth and build
industry. As SSA has very high HIV prevalence amongst ado-
lescents and youth [27], promoting the health of adolescents
and youth living with HIV is essential for the region to make
meaningful progress towards the SDGs over and beyond
health-related SDGs.
HIV-infected adolescents are a neglected group [28]. Recent
systematic reviews indicate that the evidence base for adher-
ence and retention-enhancing interventions amongst HIV-
infected adolescents and youth is very sparse, and that most
studies focussed on high-income countries and had low partic-
ipant numbers [23,28,29]. These reviews conclude that identi-
fying effective interventions that improve ART outcomes
amongst adolescents is overdue. Evidence of the longer-term
effectiveness and cost-effectiveness of adherence and reten-
tion-enhancing interventions are particularly lacking [30]. The
limited evidence that exists suggests that interventions that
include individualized psychosocial support, counselling and
education, and the provision of specific adolescent-tailored
services are promising and require further investigation
[23,28,29].
SSA also has critical shortages of professional healthcare
workers–particularly aggravated due to the HIV/AIDS epi-
demic–and needs to substantially increase its health workforce
to attain its development goals [31,32]. SDG target 3c is to
substantially increase the recruitment, development and train-
ing of the health workforce in developing countries [1]. Com-
munity-based support (CBS) programmes are task-shifting
healthcare interventions involving lay healthcare workers that
have been developed to increase the health workforce at lim-
ited cost in developing countries [33,34]. Amongst others,
CBS programmes have aimed to support HIV-infected adults
receiving ART [35]. The effectiveness of CBS for adolescents
receiving ART requires evaluation, and cost-effectiveness eval-
uations of CBS are lacking [36].
South Africa has the greatest number of people living with
HIV globally, and is showing poor performance regarding its
HIV-related SDG target [3,37]. South Africa also has one of
the most unequal societies worldwide [38]. South Africa’s
unemployment rate (27%) is amongst the ten highest national
unemployment rates globally, [39,40] with youth unemploy-
ment being approximately 50% [41]. Almost two-thirds of
young South African children live in poverty, and 20% of the
population live in extreme poverty [38,42].
This study aimed to evaluate the effectiveness and cost-
effectiveness of a large CBS programme for HIV-infected ado-
lescents and youth receiving ART (with five years of patient
outcomes) in four South African provinces.
2 | METHODS
A retrospective cohort study was performed at 47 public ART
facilities, using routinely collected clinical data. The facilities
were located in KwaZulu-Natal, Western Cape, Eastern Cape
and Mpumalanga provinces, in both urban (33 facilities) and
rural areas (14 facilities). Included facilities were all facilities
supported by Kheth’Impilo, a non-profit organization, which
had a CBS programme for adolescents and youth. Kheth’Im-
pilo supports the South African Department of Health with
public health systems strengthening. The majority were pri-
mary healthcare facilities, and six were secondary-level hospi-
tals. Antenatal HIV prevalence in these provinces varied
between 18.2% and 37.4% [43]. Co-infection with tuberculosis
amongst adolescents and youth starting ART in South Africa is
high (9% to 13%) [13].
Antiretroviral-naive adolescents and youth aged 10 to
24 years who initiated ART between 01 January 2004 and 30
September 2010 were included. Follow-up was until mortality,
loss to follow-up (LTFU), documented transfer-out to other
sites, 30 September 2011 (database closure) or five years on
ART (whichever occurred first). To evaluate the effectiveness
of CBS, ART outcomes were compared between adolescents
and youth who received CBS plus standard clinic-based care
versus adolescents and youth who received standard care
only. During the pre-ART preparation period, patients initiating
ART were evaluated by a facility-based community co-ordina-
tor (named a “site-facilitator”), who assigned patients in a non-
randomized manner to receive CBS in addition to usual care if
the following criteria were fulfilled: CBS-workers were active
in the area of the patient’s home, CBS-worker capacity was
available, and patient consent was obtained. As the develop-
ment of the CBS programme was progressive, few patients
initially received CBS but this increased as the programme
expanded. Clinical and socioeconomic factors were not criteria
in the allocation of patients to receive CBS. For analyses,
patients were assigned to the CBS group if they were allo-
cated to and received support from a named CBS-worker
from ART initiation.
2.1 | CBS intervention
CBS-workers are clinic-linked, lay community health workers
who provided ART patient support by undertaking home visits
to ascertain and address household challenges impacting on
clinic attendance and adherence. CBS-workers resided in low
socioeconomic, high HIV-prevalence areas. Preference was
given to employing previously unemployed people as CBS-
workers. They were trained regarding HIV and tuberculosis
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(TB) infection and treatment, including addressing psychoso-
cial issues impacting adherence. Support started from the time
of pre-ART preparation and continued throughout long-term
care. Patient, family and household issues assessed by CBS-
workers included nutrition security, substance abuse, mental
health including depression, domestic violence, non-disclosure,
and HIV-related stigma and discrimination. Issues were dis-
cussed at clinic multidisciplinary team meetings and interven-
tions agreed by the team were implemented by the CBS-
worker as appropriate. CBS included providing one-on-one
counselling regarding adherence, and support and referral for
psychosocial problems and nutrition security. Participants
were provided with information and education regarding sex-
ual and reproductive health and family planning. Adolescents’
carers were offered educational sessions regarding HIV/TB
information, medication adherence, and nutrition. Adolescents
and youth who defaulted clinic visits were traced by CBS-
workers. Eligibility for government social assistance grants (for
poverty relief) was assessed and support provided to obtain
these where eligible.
Participants were scheduled for weekly visits during the
first months following ART initiation, then monthly for at least
six months. Once stable, home visits were performed at least
quarterly, but if clinic visits were delayed, home visit fre-
quency increased. Health promotion education and symptom
screening for TB, opportunistic infections and sexually trans-
mitted infections (STIs) were performed, with referral to clin-
ics for further management if indicated.
CBS-workers had a specific geographic area which they sup-
ported and were assigned 80 to 120 patients each. Career
development of CBS-workers was encouraged, with certain
CBS-workers subsequently employed as social auxiliary work-
ers or home-based care co-ordinators [44].
2.2 | Outcomes and definitions
The primary outcomes were as follows: time to all-cause mor-
tality after starting ART, and time till LTFU after starting ART.
Attrition was defined as a combined endpoint due to patient
losses due to either mortality or LTFU. The secondary out-
comes were as follows: (i) Adherence to ART measured using
Medication Possession Ratios (MPRs)–an adherence measure
derived from pharmacy refill data (number of days of dis-
pensed medication divided by the number of days between
the first and last pharmacy refill during the study period)
[45,46]; (ii) CD4 cell count increases between months 0 and
36 after starting ART; (iii) CD4 count slope (mean change in
CD4 count per month) between months 0 to 6 and 6 to 60;
and (iv) the proportion of patients not achieving virological
suppression after three years and during the fifth year of
ART. We were primarily interested in longer-term immunologi-
cal reconstitution and virological outcomes and not the initial
rapid rise in CD4 count following ART initiation [47].
Deaths were recorded as reported by professional health-
care workers or family members. Patients were defined as
LTFU if they were not known to have died or to have trans-
ferred out (as documented in site databases), and had no
visit to the site for six months or more prior to database clo-
sure [48,49]. Patients who returned to care after treatment
interruptions were considered remaining in care. The date of
last contact was assigned for the outcome of mortality or
LTFU in time-to event analyses, with one day of follow-up
added for patients who did not return after initiating ART to
include them in analyses. Patients documented as transferring
to other facilities were censored on the last clinic visit date.
Patients who did not receive CBS who missed appointments
were traced by telephone or a district tracing team would
visit the home where available. All patients visited the clinic
at a frequency determined by clinic professional staff (gener-
ally monthly). Virological suppression was defined as viral
load <400 copies/ml. Laboratory measurements were
performed by the South African National Health Laboratory
Service.
Individual-level patient data were collected prospectively for
programme monitoring purposes by designated site-based
data capturers at each visit using standardized custom-
designed databases, which were regularly pooled to a data
warehouse, using standardized operating procedures. Site
databases were designed in Microsoft Access®, and were used
for clinical data collection and patient and clinic management.
Regular data cleaning and quality control procedures were
implemented.
Participant baseline characteristics were compared with
medians, interquartile ranges and percentages, and binary
variables were compared with risk ratios and 95% confidence
intervals. Outcomes were by intention-to-treat ignoring
changes in exposure status after ART initiation. Cumulative
incidence functions were used to calculate time till mortality
or LTFU, using a competing-risks approach. Multivariable Cox
regression and Fine and Grey competing-risks regression
were used to compare mortality and LTFU between patients
who received and did not receive CBS, controlling for demo-
graphic, clinical and site-related confounding. To account for
clustering of observations within sites, stratified Cox regres-
sion was conducted allowing the baseline hazard for each site
to vary [50], and for the competing-risks models site was
included as a fixed effect. Incidence rate ratios of attrition
were calculated stratified by site, with the combined estimate
calculated using Mantel–Haenszel weights.
Mean MPR was analysed using generalized estimating equa-
tions specifying for clustering within sites and using Huber–
White (robust) variance estimates. MPR was also analysed as
a binary variable with mixed-effects logistic regression includ-
ing site as a random intercept, using a threshold MPR of
≥95% to indicate high adherence. CD4 count increases were
analysed with linear regression, and CD4 cell slopes were
analysed with multilevel mixed-effects linear regression includ-
ing site and patient as random effects to account for the lon-
gitudinal nature of the data and clustering within sites.
Models were adjusted for ART duration and baseline variables
were included as fixed effects. Proportions of patients not
achieving viral suppression were analysed using mixed-effects
logistic regression.
To impute missing baseline covariate data, multiple imputa-
tions by chained equations were conducted using 20 imputed
datasets, under the assumption that missing data were likely
missing at random. Multivariable analyses were run on each
data set that included the imputed values and the results
combined, using Rubin rules [51].
All available plausible demographic, clinical and site-related
variables were considered as potential confounders and were
included in multivariable models when their inclusion altered
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the association between CBS and the outcomes or were sig-
nificantly associated with the outcomes with p < 0.05. Modifi-
cation of the effect of CBS on outcomes was assessed by
stratifying effect measures by plausible modifiers. The number
needed to treat (NNT) to prevent a case of death or LTFU
were calculated as appropriate for time-to-event outcomes
[52].
2.3 | Cost-effectiveness analyses
A top-down expenditure approach was used to determine the
incremental cost of CBS to usual ART care from a provider
perspective. Expenditure of the CBS programme according to
the financial records of the programme were collected, which
included costs of human resources, training, management and
administration, infrastructure and equipment, and monitoring
and evaluation over a two-year period between 01 April 2011
and 31 March 2013. The cost of usual ART patient care was
not considered and was assumed to be equal between
patients with and without CBS. The number of patient-years
of CBS during this period was calculated from programme
monitoring data.
The cost outcomes were: (i) average cost of CBS per
patient-year of support, and (ii) cost-effectiveness defined as
cost per patient-loss (through death or LTFU) averted. The
effectiveness of CBS in preventing patient attrition at annual
intervals after starting ART (compared to usual care) was cal-
culated as the difference in patient attrition between patients
who did and who did not receive CBS (estimated from a strat-
ified Cox model) divided by attrition amongst patients who did
not receive CBS [53]. Incremental cost-effectiveness ratios
(ICERs) were calculated from one through five years of treat-
ment. For cost calculations, patients lost to care were consid-
ered lost at the mid-point of each year. Costs were converted
to United States dollars at the average exchange rate of ZAR
1 = US$0.1219 in 2012 [54]. For ICERs, costs and patient
losses averted were discounted at 3% per annum [55]. Analy-
ses were conducted with Stata® version 13.1 (College Station,
TX, USA), and Microsoft Excel®. The University of Cape Town
Human Research Ethics Committee provided the studies ethi-
cal approval, and the study conformed to the Declaration of
Helsinki ethical principles.
3 | RESULTS
Database records of 85,997 patients who initiated ART were
screened for inclusion, with the following excluded: 3756
patients aged <10 years when starting ART; 74,123 aged
≥25 years; and 1412 who started ART after the study enrol-
ment period. Thus 6706 participants were included, of whom
2100 (31.3%) received CBS and 4606 (68.7%) who received
standard care only. Most (82.4%) participants were female
and 1810 (27.0%) were aged 10 to 19 years. At ART initia-
tion, participants who received CBS had: a higher proportion
with advanced clinical stage disease (World Health Organiza-
tion (WHO) stages III/IV), a slightly higher median CD4 count,
a higher proportion who received concomitant TB treatment,
a higher proportion who were pregnant, a higher proportion
who attended rural facilities and a higher proportion who
attended primary healthcare clinics (Table 1). The proportion
of patients who received CBS increased from 19.3% to 33.5%
during the study period.
During 9215 person-years of follow-up, 87 (4.1%) and 256
(5.6%) of participants who received and did not receive CBS
were reported as having died, respectively (p = 0.015). A fur-
ther 286 (13.6%) and 885 (19.2%) became LTFU amongst
those who received and did not receive CBS, respectively
(p < 0.0001). 375 (8.5%) participants transferred out. After
five years of ART, the cumulative incidence of mortality
amongst adolescents and youth who received and did not
receive CBS was 8.3% and 10.8%, respectively (p = 0.027),
and the cumulative incidence of LTFU was 29.9% and 38.9%,
respectively (p < 0.0001) (Figure 1).
For multivariable analyses, the proportions of imputed
baseline values were: TB treatment status-5.6%; pregnancy
status-5.3%; CD4 count-17.1%; initial regimen-15.6%; WHO
stage-34.0%. After controlling for confounding using multivari-
able Cox regression, participants who received CBS had a sig-
nificantly reduced probability of mortality, adjusted hazard
ratio (aHR) = 0.52 (95% CI: 0.37 to 0.73; p < 0.0001)
(Table 2). Estimates from the competing-risks regression mod-
els were similar. Adolescents and youth who received CBS
had a 40% reduced probability of becoming LTFU, aHR = 0.60
(95% CI: 0.51 to 0.71; p < 0.0001). The effect of CBS on
LTFU was more pronounced at rural facilities, aHR = 0.43
(95% CI: 0.30 to 0.62) and slightly more pronounced amongst
pregnant women, aHR = 0.53 (95% CI: 0.31 to 0.92).
The NNT to prevent one case of mortality after one and
three years was 6.4 (95% CI: 3.6 to 16.7) and 5.3 (3.2 to
13.0), respectively, and the NNT to prevent one case of LTFU
after one and three years was 6.0 (95% CI: 4.4 to 9.4) and
5.4 (4.2 to 8.0), respectively.
Considering the combined endpoint of attrition, the inci-
dence rate of attrition was 12.9 cases/100 person-years (95%
CI: 11.7 to 14.3) amongst adolescents and youth who
received CBS, and 18.0 cases/100 person-years (95% CI: 17.0
to 19.1) amongst adolescents and youth without CBS, inci-
dence rate ratio (stratified by site) = 0.55 (95% CI: 0.48 to
0.64; p < 0.0001).
Mean MPR was similar between patients with and without
CBS; 82.5% and 83.0%, respectively, adjusted mean differ-
ence = 1.0 % (95% CI: 2.6% to 0.5%), p = 0.20 (Table 3).
There was no difference in the proportion of patients who
achieved high adherence (MPR ≥95%), viz. 35.4% and 35.8%
amongst patients with and without CBS, respectively, adjusted
odds ratio (aOR) = 1.00 (95% CI: 0.86 to 1.19; p = 0.92).
CD4 count increases were 384.5 cells/ll and 366 cells/ll
amongst adolescents and youth with and without CBS, respec-
tively, after 36 months. CD4 count slope between months 6
to 60 in adolescents and youth with and without CBS was 6.7
cells/ll/month and 7.1 cells/ll/month, respectively, with no dif-
ference in multivariable analyses; coefficient = 1.28 cells/ll/
month (95% CI: 1.12 to 3.68; p = 0.30).
The proportions of adolescents with and without CBS who
failed to achieve virological suppression after three years
were similar, aOR = 0.96 (95% CI: 0.41 to 2.28), p = 0.93.
During the fifth year of ART, the proportions with and without
CBS who failed to achieve virological suppression were 18.8%
and 37.2%, respectively, with the adjusted effect measure
approaching a significant difference in favour of CBS,
aOR = 0.24 (95% CI: 0.06 to 1.03), p = 0.055.
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3.1 | Cost-effectiveness results
The average cost of CBS was US$49.5/patient/year, with 84%
spent on human resources (Table 4). The entire programme
employed 576 CBS-workers. The effectiveness of CBS in
reducing patient attrition ranged from 42.2% after one year
to 35.9% after five years. The incremental cost of CBS per
patient-loss averted after one, two and five years was US
$600, US$776 and US$1149, respectively (Table 5).
4 | DISCUSSION
The SDGs are opportune to improve the health and wellbeing
of disadvantaged groups globally. Government commitment to
the SDGs needs to be translated into programmes that can
deliver on the wide-ranging goals and accompanying targets.
The SDG targets are interrelated and overlap; notably 28 tar-
gets across 11 goals are health-related [3,26]. To reach the
SDGs for adolescents by 2030, the importance of innovations
Table 1. Characteristics of adolescents and youth at antiretroviral treatment initiation who received and did not receive CBS in
South Africa
Total (n = 6706)
Did not received
CBS (n = 4606)
Received CBS
(n = 2100)
Risk ratio (CBS vs. no
CBS) (95% CI)a
Female, n (%) (n = 6706) 5523 (82.4) 3752 (81.5) 1771 (84.3) 1.04 (1.01 to 1.06)
Median age, years, (IQR) (n = 6706) 22.4 (19.6 to 23.9) 22.4 (19.5 to 23.9) 22.5 (19.9 to 23.9)
Age categories, n (%) (n = 6706)
Ages 10 to 19 years 1810 (27.0) 1268 (27.5) 542 (25.8) 0.93 (0.86 to 1.02)
Ages 20 to 24 years 4896 (73.0) 3338 (72.5) 1558 (74.2)
WHO clinical stage, n (%) (n = 4424)
I/II 1564 (35.4) 1171 (37.5) 393 (30.1)
III/IV 2860 (64.7) 1949 (62.5) 911 (69.9) 1.12 (1.06 to 1.17)
CD4 cell count, cells/ll, median (IQR) (n = 5560) 136 (70 to 187) 131 (65 to 182) 145 (82 to 195)
Pregnancy amongst females, n (%) (n = 5166)
Not pregnant 4512 (87.3) 3031 (88.4) 1481 (85.3)
Pregnant 654 (12.7) 399 (11.6) 255 (14.7) 1.26 (1.09 to 1.46)
Received tuberculosis treatment, n (%) (n = 6332)
No 5623 (88.8) 3831 (89.6) 1792 (87.1)
Yes 709 (11.2) 443 (10.4) 266 (12.9) 1.25 (1.08 to 1.44)
Initial regimen, n (%) (n = 5657)
d4T-3TC-EFV 2792 (49.4) 1961 (52.5) 831 (43.2)
d4T-3TC-NVP 2006 (1342) 1342 (36.0) 664 (34.5)
ZDV-3TC-EFV 38 (0.7) 19 (0.5) 19 (1.0)
ZDV-3TC-NVP 106 (1.9) 37 (1.0) 69 (3.6)
TDF-3TC-EFV 339 (6.0) 163 (4.4) 176 (9.2)
TDF-3TC-NVP 322 (5.7) 184 (4.9) 138 (7.2)
Other 54 (1.0) 27 (0.7) 27 (1.4)
Year of starting ART, n (%)(n = 6706)
2004 to 2005 218 (3.3) 176 (3.8) 42 (2.0)
2006 to 2007 1384 (20.6) 1038 (22.5) 346 (16.5)
2008 to 2010 5104 (76.1) 3392 (73.6) 1712 (81.5)
Location of site attended, n (%) (n = 6706)
Urban 5238 (78.1) 3784 (82.2) 1454 (69.2)
Rural 1468 (21.9) 822 (17.9) 646 (30.8) 1.72 (1.58 to 1.88)
Hospital-based clinic/primary healthcare clinic attended, n (%) (n = 6706)
Hospital 1612 (24.0) 1407 (30.6) 205 (9.8)
Primary healthcare clinic 5094 (76.0) 3199 (69.5) 1895 (90.2) 1.30 (1.27 to 1.33)
Province, n (%) (n = 6706)
Western Cape 803 (12.0) 523 (11.4) 280 (13.3)
Eastern Cape 1259 (18.8) 587 (12.7) 672 (32.0)
KwaZulu-Natal 4035 (60.2) 3243 (70.4) 792 (37.7)
Mpumalanga 609 (9.1) 253 (5.5) 356 (17.0)
ART, antiretroviral treatment; CBS; community-based support; WHO, World Health Organization; IQR, interquartile range; CI, confidence interval;
d4T, stavudine; 3TC, lamivudine; EFV, efavirenz; NVP, nevirapine; ZDV, zidovudine; TDF, tenofovir.
aFor binary variables.
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in adolescent health involving biomedical and behavioural
interventions delivered together has recently been highlighted
[56].
Adolescents are a key group for targeting of the UNAIDS
90-90-90 HIV treatment goals [57]. In view of their poorer
ART outcomes, there have previously been calls for adoles-
cents and youth to receive specific additional support [11-
13,15]. This study has found that CBS was associated with
substantially improved retention in adolescents and youth
receiving ART, and is a low-cost intervention with reasonable
cost-effectiveness. Cost-effectiveness of CBS was greatest
during the first two years of treatment.
Improved programme retention increases the number of
HIV-infected adolescents and youth receiving ART, which
would lead to greater numbers potentially being able to
achieve viral suppression due to ART use. In turn, this can
potentially decrease sexual transmission due to ART [58,59]
and aid progress towards SDG target 3.3 to reduce HIV
incidence.
Community support has previously been found to reduce
ART programme attrition amongst adults and children [35,60].
Mechanisms underlying these improvements include defaulter
tracing, psychosocial support offered by CBS workers,
improved patient links with clinics, decreased treatment fati-
gue, improved self-management skills regarding HIV/AIDS,
greater disclosure, greater social capital and a widened com-
munity safety net [35,61,62]. The primary driver of decreased
attrition associated with CBS in this study was reduced LTFU,
with reduced mortality accounting for a small component only.
Except for a trend towards improved viral suppression at five
years amongst those who received CBS, significant differences
in immunological restitution or the adherence measure utilized
were not observed. In the absence of these, the reasons for
the difference in mortality observed are unclear and require
further research. It is plausible that CBS was associated with
health aspects not measured in this study, such as earlier
referral and treatment for incident opportunistic infections,
improvements in nutritional status or mental health, or
improved socioeconomic status through access to grants.
Future research should also incorporate more accurate mea-
sures of adherence.
In adults, the cost-effectiveness of strategies to reduce ART
patient attrition have been evaluated in two previous studies.
A hypothetical study found that interventions costing up to
US$120/person/annum with effectiveness ≥40% in reducing
attrition would be cost-effective with high degrees of regional
ART coverage [63]. A Cote d’Ivoire study found that interven-
tions preventing LTFU would result in a substantial saving of
life-years, and an intervention costing US$53 per person/an-
num would be cost-effective by international criteria (<3 times
gross domestic product per capita) if ≥28% effective [53].
Although we did not model cost-effectiveness based on dis-
ability-adjusted life years averted, CBS was found to cost US
$50/person/annum and have effectiveness between 42% to
(a)
(b)
N at risk at beginning of interval
Without CBAS    4606 2539 1134 373 126 36     
With CBAS         2100 1069 495 212 79 18 
P=0.027
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Figure 1. Cumulative incidence of (A) Loss to follow-up and (B) mortality amongst adolescents and youth starting antiretroviral treatment in
South Africa.
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36%, and would thus be expected to cost-effectively reduce
high attrition amongst SSA adolescents and youth.
The health workforce underpins every aspect of the health
system, and is the rate-limiting step in achieving universal
health coverage by 2030 [64]. There is pronounced inequity in
the distribution of health workers globally, with Africa carrying
25% of the world’s disease burden but only 1.3% of the
world’s health workers, with little progress being evident in
this regard [65,66]. To achieve health-related SDGs, task-shift-
ing to maximize the use of available funds and health workers
in the region will be essential. Efficiency and value for money
will be important priorities. Amongst children, UNICEF is pro-
moting task-shifting from professional to community health
workers to improve access to health interventions, in order to
achieve SDG target 3.2 to prevent common causes of child
mortality [67]. The CBS programme evaluated in this study
extends this model for the care of HIV-infected adolescents
and youth.
Community health workers can play a key role in attaining a
number of SDGs, including health, ending poverty and hunger,
equality, clean water and sanitation, and partnerships for
global health (SDG 17), as highlighted in the recent Kampala
statement [68,69]. Important actions to support the role of
community health workers in this regard include financial and
political support, partnerships with a range of healthcare pro-
viders, and disseminating cross-country learnings. Rigorous
research to expand the evidence base for policy and practice
to maximize the contribution and potential of community
health workers in progress towards these SDGs is vital [70].
Research priorities include the roles of cross-cutting enabling
factors such as education and accreditation of community
health workers, management, effective linkage with other pro-
fessional staff cadres, remuneration, and motivation and per-
formance [64,68]. Translating evidence to investment decisions
will also be required to enable sustainable health solutions in
pursuit of the SDGs. Including community engagement as an
additional aspect of the SDG health targets has also been
suggested [26].
Innovations in health worker training will be important in
attaining the SDGs. CBS involves training previously unem-
ployed persons living in impoverished areas and employing
them as lay health workers, and assisting their further career
development [44]. As CBS is labour-intensive, large CBS pro-
grammes will aid progress towards SDG targets 4.4, 8.5 and
8.6 (provision of skills to facilitate employment and job cre-
ation). Job-creation further impacts other health-related tar-
gets, as access to gainful employment improves the mental
and physical well-being of families and young people [26]. Pro-
vision of jobs for CBS-workers also increases income to the
lowest 40% income group (SDG target 10.1) which can sup-
port the targets to reduce poverty and food insecurity
amongst CBS-workers and their families (SDG targets 1.1, 1.2
and 2.1).
HIV-related interventions that have cross-sectoral benefits
produce development synergies and will accelerate progress
across development goals [71]. CBS-workers provided coun-
selling regarding mental health, sexual and reproductive health
(particularly for adolescent girls), nutrition counselling, and
support to access social grants. These interventions can aid
progress towards SDG target 3.4 (promotion of mental health
and wellbeing), SDG target 3.7 (universal access to sexual and
reproductive healthcare services), as well as reduce poverty
Table 4. Costs of CBS for antiretroviral treatment patients in
South Africa
Total patient-years supported 126,485
No. community workers employed 576
Item Average costs per
patient year supported,
US$ (%)a
Human resources 41.83 (84.4)
Training 5.97 (12.1)
Infrastructure and equipment 0.02 (0.05)
Clothing for CBS-workers 0.15 (0.3)
Management and administration 0.48 (1.0)
Monitoring and evaluation 0.10 (0.2)
Overhead costs 0.99 (2.0)
Total cost per patient supported/year 49.5 (100.0)
aValues in parentheses are percentages of the total cost.
Table 5. Cost-effectiveness of CBS for ART patients in South Africa
Duration of
ART (years)
Proportion of patients
retained in care (%)a Effectiveness of
intervention in reducing
patient attrition (%)b
No. patient losses
averted due to CBS
(per 100 patients
initiating ART)c
Cumulative cost of
CBS (per 100 patients
initiating ART), US$c,d
Cost-effectiveness ratio
(US$/patient-loss averted)With CBS Without CBS
1 89.3 81.5 42.2 7.6 4549 600.7
2 82.7 71.0 40.3 11.0 8561 776.3
3 76.4 61.5 38.7 13.6 12,165 892.1
4 70.7 53.5 37 15.3 15,400 1007.7
5 66.9 48.4 35.9 16.0 18,337 1149.1
aEstimated from the survivor function of a stratified Cox model.
bThe effectiveness of the CBS programme in preventing attrition (through death or loss to follow-up) was calculated as the difference in patient
attrition between patients who did and who did not receive CBS divided by attrition amongst patients who did not receive CBS.
cCosts and no. of patient losses averted were discounted at 3% per annum.
dPatients lost to the programme were considered lost at the mid-point of each year.
CBS, community-based support; ART, antiretroviral treatment.
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and hunger. As almost 85% of CBS-supported participants
were female, gender-equality progress (SDG target 5.6) is also
supported. The impact of these services was not assessed in
this evaluation; however, future economic analyses may incor-
porate the potential cross-sectoral benefits of CBS.
South Africa has recently introduced and is scaling-up
implementation of new national adherence guidelines [72]. In
line with this, CBS workers currently provide home and clinic-
based support for the initial 12 months after starting ART
and for patients who are unstable. This study’s results provide
evidence of the effectiveness of an individualized approach to
support adolescents and youth, and encourage scale-up of
implementation of these guidelines. Individual and group coun-
selling and education for adolescents have shown promise in
previous smaller studies conducted mostly in developed coun-
tries [28,29]. The role of CBS workers is currently expanding
to include facilitation of community and clinic-based adherence
clubs for stable, virologically suppressed adults from
12 months of ART and beyond.
Challenges faced by the CBS programme include the rural
context of many patients’ homes with long travel distances
and inadequate transport, and inconsistent availability of some
adolescents for follow-up counselling sessions. CBS is not a
panacea, and other important facets of comprehensive care
include youth-friendly clinical management, peer-support
groups, and integrated management of the transition from
child to adult care services [20,21].
The strengths of this study include the large sample size
drawn from many sites situated in low-income, high HIV
prevalence areas, with results thus likely being generalizable
to other SSA areas. Prospectively collected individual-level
data were collected with up to five years of patient follow-up.
Additionally, clinical as well as cost outcomes were analysed.
The study limitations include the non-random allocation of
patients to groups, with the potential for selection bias and
unmeasured or residual confounding. Effect measures were,
however, adjusted for site-related and individual-level con-
founding using multiple imputation of missing covariate values.
Differences in measured baseline characteristics were
observed between CBS and non-CBS patients; however, most
confounders associated with increased attrition were more
prevalent amongst CBS patients (advanced clinical stage dis-
ease [73], concurrent TB [74], pregnancy [75], more recent
year of starting ART [14,76], and attending rural facilities
[77]). Residual confounding is thus unlikely to have con-
founded effect measures in favour of CBS. The routine nature
of the data may have produced information bias. Mortality
was likely underestimated in both CBS and non-CBS patients,
as misclassification of patients who have died as being LTFU
is common in SSA routine ART data [78]. Patients who were
classified as LTFU may have been undocumented transfers to
other treatment sites outside the study facilities.
5 | CONCLUSIONS
The SDG process reinforces the central importance of health
in sustainable development. Greater attention to adolescent
health, particular regarding HIV/AIDS, will be critical to achieve
universal and sustainable development [56]. This study found
CBS to be a low-cost intervention associated with substantially
improved retention in adolescents and youth receiving ART,
which had reasonable cost-effectiveness. CBS for adolescents
and youth can potentially aid progress towards twelve targets
from eight health, economic, equality and education-related
SDGs. Future qualitative research may shed greater light on
mechanisms that may improve outcomes and how community-
support may be further tailored specifically for adolescents.
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